Antibody Drug Discovery

• Z. An. Therapeutic Monoclonal Antibodies: from Bench to Clinic, Editor, John Wiley and Sons, p889, Hoboken, New Jersey (October, 2009).

• Z. An. 2005. Handbook of Industrial Mycology, Editor, Marcel Dekker, p763, New York, NY.

• CMV neutralizing antigen binding proteins. US Patent 11,230,591

• Nmes1 antibodies and methods of use thereof. US20210371508A1

• Connexin (cx) 43 hemichannel-binding antibodies and uses thereof. US20210253680A1

• TARGETING LILRB4 WITH CAR-T OR CAR-NK CELLS IN THE TREATMENT OF CANCER. US Application Publication No: US 2021-0179687 A1

• Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies. United States. Patent 10889637

• LINKERS FOR ANTIBODY DRUG CONJUGATES, US20200115326A1

• NOVEL LILRB2 ANTIBODIES AND USES THEREOF, 62/970,496, 2020, filed

• NOVEL DDR1 ANTIBODIES AND USES THEREOF, WO 2021127185A1

• Leptin Antibodies, US 2021-0188970 A1

• Anti-lair1 antibodies and their uses, US20190338026A1

• Linker for antibody drug conjugate, US20200115326A1

• Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies, US 10889637 B2

• EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE, US10875912B2

• Anti-lilrb antibodies and their use in detecting and treating cancer, US10501538B2, US20200079851A1

• Egfl6 specific monoclonal antibodies and methods of their use, US10875912B2

• CMV neutralizing antigen binding proteins, US9868777B2

• HER3 specific monoclonal antibodies for diagnostic and therapeutic use US10358501B2, US20200055954A1

• Endotrophin Neutralization and Use Thereof 2013, US20170267749A1, Patent number, US9605057, US20200024333A1

• Antigen-binding proteins targeting S. aureus ORF0657n, 2009, WO/2009/029132

• Antibody antagonists of interleukin-13 receptor ?1, US8207304, 2008, WO/2008/049098

• Anti-ADDL antibodies and uses thereof, US8128930, 2012; US7731962, 2006, WO/2006/055178

• Anti-IL-13Ra1 antibodies and their uses thereof, US Patent 8,613,925, 2013

• 抗体特定消退,2008,我们7994293,2008/0193449 A1

• High affinity antibody antagonists of interleukin-13 receptor alpha 1, US10106617B2, US7754213B2, US8568722B2, US9371388B2